港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

英派藥業-B

13.020

+0.0700.54%

成交量：617.86萬

成交額：8,436.49萬

市值：36.78億

市盈率：-10.06

高：14.500

開：13.290

低：12.820

收：12.950

52周最高：47.980

52周最低：10.310

股本：2.82億

香港流通股本：2.82億

量比：2.25

換手率：2.19%

股息：- -

股息率：- -

每股收益(LYR):-1.295

淨資產收益率：--

總資產收益率：-40.35%

市淨率：4.04

市盈率(LYR):-10.06

市銷率: 26.49

資料載入中...

總覽公司新聞資訊公告

英派藥業-B(07630)發布《董事會審計委員會工作規程》明確審計委員會權限與運作

英派藥業與法瑪諾唯亞簽署獨家許可協議

中国财富网

英派藥業-B早盤升逾11% 授治療癌症產品塞納帕利獨家權利

港股異動 | 英派藥業-B(07630.HK)漲近10% 授治療癌症產品塞納帕利獨家權利或獲最多逾4億歐元及特許權費

英派藥業-B(07630.HK)與PHARMANOVIA就塞納帕利於歐洲、中東及北非、澳洲及新西蘭簽訂獨家授權協議有望獲得總計最高達4.235億歐元的交易對價

英派藥業-B與Pharmanovia達成Senaparib在歐洲、中東、北非、澳大利亞及新西蘭的獨家授權協議

英派藥業-B 2026年首場臨時股東會通過股份獎勵計劃及章程修訂

英派藥業-B(07630.HK)：將IMP3201提名為臨床前候選化合物(PCC)，為一款全新、同類首創(FIC)、靶向CEACAM5的雙載荷ADC

英派藥業-B（07630）宣佈首款靶向CEACAM5雙載荷ADC IMP3201獲選臨床前候選化合物

英派藥業－Ｂ(07630)股價下跌9.184%，現價港幣$11.57

阿斯达克财经

英派藥業-B(07630)：多項研究結果摘要獲接受於2026年歐洲腫瘤內科學會大會作壁報展示

智通财经网

英派藥業-B（07630）三項管線最新數據獲2026年ESMO大會壁報展示

英派藥業-B（07630）擬設立股份獎勵計劃並修訂公司章程

英派藥業-B（07630）將於2026年7月27日召開首次臨時股東會並暫停過户

Tencent Holdings Limited增持英派藥業-B(07630)35萬股每股作價約36.17港元

Tencent Holdings Limited增持英派藥業-B(07630.HK)35萬股每股作價約36.17港元

英派藥業-B6月股份變動月報：註冊股本增至282,461,530股

55家公司港股通新貴即將喜迎北水流入入通門檻或已抬升至102.67億港元

股東施毅增持英派藥業-B(07630)2.00萬股每股作價約35.94港元

智通财经网

《大行》高盛列出具有納入南向交易潛力半新股(表)

阿斯达克财经

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/07630/news?page=4"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"07630","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"07630\",,,,,undefined,":{"symbol":"07630","market":"HK","secType":"STK","nameCN":"英派藥業-B","latestPrice":13.02,"timestamp":1792138094538,"preClose":12.95,"halted":0,"volume":6178600,"delay":0,"changeRate":0.005405405405405427,"floatShares":282461530,"shares":282461530,"eps":-1.294715,"marketStatus":"重陽節翌日休市","change":0.07,"latestTime":"10-16 16:08:14","open":13.29,"high":14.5,"low":12.82,"amount":84364938,"amplitude":0.12973,"askPrice":13.02,"askSize":3400,"bidPrice":12.97,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-1.052,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1792459800000},"marketStatusCode":7,"adr":0,"listingDate":1778601600000,"exchange":"SEHK","adjPreClose":12.95,"openAndCloseTimeList":[[1792114200000,1792123200000],[1792126800000,1792137600000]],"volumeRatio":2.2529243603096694,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"07630\",,,,,undefined,":{"symbol":"07630","floatShares":282461530,"roa":"-40.35%","roe":"--","lyrEps":-1.294715,"volumeRatio":2.2529243603096694,"shares":282461530,"dividePrice":0,"high":14.5,"amplitude":0.12973,"preClose":12.95,"low":12.82,"week52Low":10.31,"pbRate":"4.04","psRate":"26.49","week52High":47.98,"institutionHeld":0,"latestPrice":13.02,"committee":-0.888889,"eps":-1.294715,"divideRate":0,"volume":6178600,"delay":0,"ttmEps":-1.052,"open":13.29,"prevYearClose":20.1,"prevWeekClose":13.02,"prevMonthClose":14.07,"prevQuarterClose":14.07,"fiveDayClose":12.68,"twentyDayClose":11.28,"sixtyDayClose":12.06},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/07630\",params:#limit:5,,,undefined,":[{"date":"2026-08-31","symbol":"07630","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1788139800000,"name":null,"time":"","dateTimestamp":1788105600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"07630\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"07630\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1782403200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/07630\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"07630","date":"2026-10-15","current":-12.376426,"percent":0.607477,"low":-34.323153,"twenty":-29.852178,"median":-13.23402,"eighty":-10.652923,"high":-8.821219,"avg":-17.72259,"sd":8.718874,"marketCap":3657876813},"quantilePoints":[{"date":"2026-05-15","current":-32.36994,"twenty":-32.973318,"median":-32.357426,"eighty":-26.127101,"marketCap":11057651805},{"date":"2026-05-22","current":-30.548005,"twenty":-32.354923,"median":-30.958502,"eighty":-28.393426,"marketCap":10411425401},{"date":"2026-05-29","current":-32.218614,"twenty":-32.294393,"median":-30.958502,"eighty":-30.148817,"marketCap":11018988687},{"date":"2026-06-05","current":-29.849738,"twenty":-32.359929,"median":-31.257987,"eighty":-30.148817,"marketCap":10223633112},{"date":"2026-06-12","current":-29.369689,"twenty":-32.33377,"median":-30.548005,"eighty":-29.705347,"marketCap":10052410732},{"date":"2026-06-18","current":-29.78235,"twenty":-32.303072,"median":-30.338658,"eighty":-29.742668,"marketCap":10218109810},{"date":"2026-06-26","current":-29.297581,"twenty":-32.241427,"median":-30.11999,"eighty":-29.607619,"marketCap":10002701008},{"date":"2026-07-03","current":-16.26247,"twenty":-32.218614,"median":-29.994357,"eighty":-29.297581,"marketCap":5556442415},{"date":"2026-07-10","current":-15.780707,"twenty":-31.493905,"median":-29.916258,"eighty":-25.475578,"marketCap":5385220035},{"date":"2026-07-17","current":-11.297625,"twenty":-31.022068,"median":-29.816044,"eighty":-15.922995,"marketCap":3869073471},{"date":"2026-07-24","current":-9.271485,"twenty":-30.958502,"median":-29.609087,"eighty":-15.602668,"marketCap":3175898995},{"date":"2026-07-31","current":-10.646015,"twenty":-30.630104,"median":-29.369689,"eighty":-13.307417,"marketCap":3653664669},{"date":"2026-08-07","current":-10.047131,"twenty":-30.493855,"median":-29.24895,"eighty":-10.58915,"marketCap":3454825776},{"date":"2026-08-14","current":-10.299125,"twenty":-30.36699,"median":-25.475578,"eighty":-10.316459,"marketCap":3545960269},{"date":"2026-08-21","current":-10.772628,"twenty":-30.33128,"median":-16.418396,"eighty":-10.292557,"marketCap":3717182649},{"date":"2026-08-28","current":-12.490535,"twenty":-30.224959,"median":-15.896725,"eighty":-10.316459,"marketCap":4310937679},{"date":"2026-09-04","current":-14.62831,"twenty":-30.072679,"median":-15.691688,"eighty":-10.353511,"marketCap":4403575252},{"date":"2026-09-11","current":-12.087934,"twenty":-30.026033,"median":-14.57977,"eighty":-10.495083,"marketCap":3643753737},{"date":"2026-09-18","current":-12.193817,"twenty":-29.977617,"median":-13.665771,"eighty":-10.535977,"marketCap":3680473735},{"date":"2026-09-25","current":-12.65778,"twenty":-29.936332,"median":-13.862539,"eighty":-10.54718,"marketCap":3813230655},{"date":"2026-10-02","current":-13.309453,"twenty":-29.921275,"median":-13.342238,"eighty":-10.553476,"marketCap":4013778341},{"date":"2026-10-09","current":-11.861614,"twenty":-29.878786,"median":-13.325845,"eighty":-10.610057,"marketCap":3581612200},{"date":"2026-10-15","current":-12.092826,"twenty":-29.852178,"median":-13.23402,"eighty":-10.652923,"marketCap":3657876813}],"updateTime":1792423640340},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"07630\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1122801606","title":"英派藥業-B(07630)發布《董事會審計委員會工作規程》 明確審計委員會權限與運作","url":"https://stock-news.laohu8.com/highlight/detail?id=1122801606","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122801606?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 20:00","pubTimestamp":1785499247,"startTime":"0","endTime":"0","summary":"2024年X月XX日，英派药业-B公告披露《南京英派药业股份有限公司董事会审计委员会工作规程》，以强化董事会决策功能、完善内部控制并确保有效监督。委员会主席由独立非执行董事担任。公司承诺向审计委员会提供履职所需资源。英派药业-B表示，《工作规程》的实施将进一步规范审计委员会运作，强化公司治理结构，并确保持续满足《公司法》及《上市规则》要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655330921","title":"英派藥業與法瑪諾唯亞簽署獨家許可協議","url":"https://stock-news.laohu8.com/highlight/detail?id=2655330921","media":"中国财富网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655330921?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 14:28","pubTimestamp":1785479299,"startTime":"0","endTime":"0","summary":"7月30日，英派药业（07630.HK）宣布与法玛诺唯亚Pharmanovia签订独家许可合作协议，授予其在欧洲、中东、北非、澳大利亚及新西兰地区对塞纳帕利（senaparib）用于晚期上皮性高级别卵巢癌、输卵管癌及原发性腹膜癌维持单药治疗的独家生产、研发及商业化权利。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607313828228360.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607313828228360.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655233805","title":"英派藥業-B早盤升逾11% 授治療癌症產品塞納帕利獨家權利","url":"https://stock-news.laohu8.com/highlight/detail?id=2655233805","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655233805?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 09:45","pubTimestamp":1785462300,"startTime":"0","endTime":"0","summary":"模拟交易客户端英派药业-B早盘涨超11%，截至发稿，股价上涨11.02%，报12.79港元，成交额99.69万港元。7月30日，英派药业宣布与全球专业制药公司Pharmanovia达成独家合作，授予Pharmanovia在欧洲、中东、北非、澳大利亚及新西兰地区对塞纳帕利用于晚期上皮性高级别卵巢癌、输卵管癌及原发性腹膜癌维持单药治疗的独家生产、研发及商业化权利。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-07-31/doc-iniksaik9401431.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655384803","title":"港股異動 | 英派藥業-B(07630.HK)漲近10% 授治療癌症產品塞納帕利獨家權利 或獲最多逾4億歐元及特許權費","url":"https://stock-news.laohu8.com/highlight/detail?id=2655384803","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655384803?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 09:34","pubTimestamp":1785461681,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655873808","title":"英派藥業-B(07630.HK)與PHARMANOVIA就塞納帕利於歐洲、中東及北非、澳洲及新西蘭簽訂獨家授權協議 有望獲得總計最高達4.235億歐元的交易對價","url":"https://stock-news.laohu8.com/highlight/detail?id=2655873808","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655873808?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 18:20","pubTimestamp":1785406817,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164331807","title":"英派藥業-B與Pharmanovia達成Senaparib在歐洲、中東、北非、澳大利亞及新西蘭的獨家授權協議","url":"https://stock-news.laohu8.com/highlight/detail?id=1164331807","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164331807?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 18:19","pubTimestamp":1785406779,"startTime":"0","endTime":"0","summary":"英派药业-B（IMPACT THERAP-B，股票代码：07630）近日宣布，已与Pharmanovia公司签署了一项独家许可协议。根据该协议，英派药业将其在研药物Senaparib的权益授予Pharmanovia，覆盖范围广泛，包括欧洲、中东、北非、澳大利亚以及新西兰等地区。这一战略合作不仅弥补了英派药业在相关区域的布局空白，也为其全球扩张注入了新动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145155539","title":"英派藥業-B 2026年首場臨時股東會通過股份獎勵計劃及章程修訂","url":"https://stock-news.laohu8.com/highlight/detail?id=1145155539","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145155539?lang=zh_tw&edition=fundamental","pubTime":"2026-07-27 18:56","pubTimestamp":1785149762,"startTime":"0","endTime":"0","summary":"南京英派药业股份有限公司7月27日公告，其2026年第一次临时股东会已于2026年7月27日召开，并就两项特别决议进行投票表决。上述两项议案均获得三分之二以上赞成票，按特别决议正式通过。截至股东会召开日，公司已发行H股总数为282,461,530股。经股东批准的组织章程细则修订自2026年7月27日起生效。修订后的章程将刊载于香港联交所网站及公司官网。全部执行董事、非执行董事及独立非执行董事均以现场或电子方式参加会议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654060630","title":"英派藥業-B(07630.HK)：將IMP3201提名為臨床前候選化合物(PCC)，為一款全新、同類首創(FIC)、靶向CEACAM5的雙載荷ADC","url":"https://stock-news.laohu8.com/highlight/detail?id=2654060630","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654060630?lang=zh_tw&edition=fundamental","pubTime":"2026-07-27 07:41","pubTimestamp":1785109287,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148850396","title":"英派藥業-B（07630）宣佈首款靶向CEACAM5雙載荷ADC IMP3201獲選臨床前候選化合物","url":"https://stock-news.laohu8.com/highlight/detail?id=1148850396","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148850396?lang=zh_tw&edition=fundamental","pubTime":"2026-07-27 07:35","pubTimestamp":1785108932,"startTime":"0","endTime":"0","summary":"2026年7月27日，英派药业-B发布自愿公告称，公司已正式将IMP3201提名为临床前候选化合物。IMP3201是一款同类首创、靶向CEACAM5的双载荷抗体-药物偶联物，基于公司自主研发的支链连接子双载荷ADC技术平台开发，是该平台产出的首个PCC。根据香港联合交易所有限公司证券上市规则第18A.05条，英派药业-B提醒股东及潜在投资者：公司无法保证最终能够成功开发、制造及/或商业化IMP3201，投资者在买卖公司股份时应保持审慎。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653732920","title":"英派藥業－Ｂ(07630)股價下跌9.184%，現價港幣$11.57","url":"https://stock-news.laohu8.com/highlight/detail?id=2653732920","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653732920?lang=zh_tw&edition=fundamental","pubTime":"2026-07-22 14:45","pubTimestamp":1784702700,"startTime":"0","endTime":"0","summary":"[下跌股]英派药业－Ｂ(07630) 股价在下午02:45比前收市价下跌9.184%，现股价为港币$11.57。至目前为止，今日最高价为$12.74，而最低价为$11.57。总成交量为28.8万股，总成交金额为港币$351.854万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126135511023_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126135511023_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2607223229/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2607223229/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652684382","title":"英派藥業-B(07630)：多項研究結果摘要獲接受於2026年歐洲腫瘤內科學會大會作壁報展示","url":"https://stock-news.laohu8.com/highlight/detail?id=2652684382","media":"智通财经网","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652684382?lang=zh_tw&edition=fundamental","pubTime":"2026-07-20 07:38","pubTimestamp":1784504331,"startTime":"0","endTime":"0","summary":"智通财经APP讯，英派药业-B 发布公告，三个主要管线项目的最新临床数据已获接受于2026年欧洲肿瘤内科学会大会作壁报展示。欧洲肿瘤内科学会大会是全球肿瘤学领域最具影响力的学术会议之一，本年度的大会将于2026年10月23日至27日在西班牙马德里举行。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469474.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"英派药业-B(07630)：多项研究结果摘要获接受于2026年欧洲肿瘤内科学会大会作壁报展示","news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176490454","title":"英派藥業-B（07630）三項管線最新數據獲2026年ESMO大會壁報展示","url":"https://stock-news.laohu8.com/highlight/detail?id=1176490454","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176490454?lang=zh_tw&edition=fundamental","pubTime":"2026-07-20 07:35","pubTimestamp":1784504139,"startTime":"0","endTime":"0","summary":"2026年7月20日，英派药业-B发布自愿公告称，公司三项核心管线项目的最新临床研究数据获欧洲肿瘤内科学会2026年大会接纳，并将在10月23日至27日于西班牙马德里举行的会议上以壁报形式展示。其欧洲上市许可申请已于2025年8月获欧洲药品管理局受理，预计2026年下半年可获批。英派药业-B提示，根据香港联交所《上市规则》第18A.05条，公司无法保证塞纳帕利在新增适应症的开发一定成功，也无法保证IMP1734及IMP1707最终获批上市。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193557412","title":"英派藥業-B（07630）擬設立股份獎勵計劃 並修訂公司章程","url":"https://stock-news.laohu8.com/highlight/detail?id=1193557412","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193557412?lang=zh_tw&edition=fundamental","pubTime":"2026-07-10 21:30","pubTimestamp":1783690255,"startTime":"0","endTime":"0","summary":"2026年7月10日，英派药业-B公告称，董事会已决议向股东大会提呈两项议案：一是建议采纳《2026年股份奖励计划》，二是建议修订公司组织章程细则。上述两项议案均须经公司股东在临时股东大会上审议并获通过后方可生效。截至公告披露日，英派药业-B董事会成员包括：执行董事蔡遂雄博士、田野博士、马宁女士；非执行董事徐聪博士、Qiang Xu博士、刘涛先生；独立非执行董事郭明博士、萧志雄先生、邵黎明博士。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142925850","title":"英派藥業-B（07630）將於2026年7月27日召開首次臨時股東會並暫停過户","url":"https://stock-news.laohu8.com/highlight/detail?id=1142925850","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142925850?lang=zh_tw&edition=fundamental","pubTime":"2026-07-08 19:20","pubTimestamp":1783509637,"startTime":"0","endTime":"0","summary":"英派药业-B7月8日公告，公司拟于2026年7月27日（星期一）举行2026年第一次临时股东会。为确定股东出席及投票资格，公司将于2026年7月22日（星期三）至2026年7月27日（星期一）暂停办理股份过户登记手续。在2026年7月27日名列股东名册的股东，或其委任代表或获授权公司代表，均可出席并投票。根据公告披露，董事会目前由3名执行董事、3名非执行董事及3名独立非执行董事组成。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649702626","title":"Tencent Holdings Limited增持英派藥業-B(07630)35萬股 每股作價約36.17港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2649702626","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649702626?lang=zh_tw&edition=fundamental","pubTime":"2026-07-06 19:36","pubTimestamp":1783337776,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，6月30日，Tencent Holdings Limited增持英派药业-B(07630)35万股，每股作价36.1719港元，总金额约为1266.02万港元。增持后最新持股数目约为1988.05万股，持股比例为7.04%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1463687.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4504","IEMG","EWH","07630","BK1161","BK4585","BK4588","BK4550","BK4581","EDZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649626700","title":"Tencent Holdings Limited增持英派藥業-B(07630.HK)35萬股 每股作價約36.17港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2649626700","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649626700?lang=zh_tw&edition=fundamental","pubTime":"2026-07-06 19:36","pubTimestamp":1783337776,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117782722","title":"英派藥業-B6月股份變動月報：註冊股本增至282,461,530股","url":"https://stock-news.laohu8.com/highlight/detail?id=1117782722","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117782722?lang=zh_tw&edition=fundamental","pubTime":"2026-07-06 17:11","pubTimestamp":1783329061,"startTime":"0","endTime":"0","summary":"南京英派药业股份有限公司（英派药业-B, 07630）于2026年7月6日披露了截至2026年6月30日的股份变动月报。报告期内，公司完成了超额配股权益的行使，新发行并配发6,296,400股H股，使注册股本由276,165,130股增至282,461,530股。\n本月无股份购回、注销及库藏股变动，也未披露任何新的股份期权或股权激励计划。公司表示已遵守香港联合交易所有限公司《上市规则》及相关法律法规要求。公告由执行董事兼首席执行官蔡遂雄签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647453054","title":"55家公司港股通新貴即將喜迎北水流入 入通門檻或已抬升至102.67億港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2647453054","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647453054?lang=zh_tw&edition=fundamental","pubTime":"2026-07-01 10:09","pubTimestamp":1782871774,"startTime":"0","endTime":"0","summary":"核心规则：市值门槛动态调整截至2026年6月30日，港股通实际纳入门槛已升至102.67亿，剔除门槛达66.89亿。这一指标直接决定了个股在指数中的权重与港股通资格。对于不同上市时长的公司，要求有所不同：对于上市公司而言，维持日均万五左右的换手率是保住港股通资格的关键。数据截止日为每年的6月30日和12月31日，这也是上市公司\"冲关\"港股通的关键时间窗口。","market":"hk","thumbnail":"https://static.tigerbbs.com/0cf777090175126e4590c3b8afdfe41e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/0cf777090175126e4590c3b8afdfe41e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461288.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02726","01609","07630","00100","00600","03661","06658","BK4585","03625","00863","02729","02335","02553","06106","06656","03388","02142","01286","06636","01956","06872","06938","07666","02632","02672","03277","01879","02526","00412","01081","02670","01866","02723","01191","BK4588","01511","02696","06675","03310","01651","01392","01672","02616","09637","01236","01133","07688","03355","01440","01779","00340","00068","02272","09630","00376","01021","03887"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2647770353","title":"股東施毅增持英派藥業-B(07630)2.00萬股 每股作價約35.94港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2647770353","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647770353?lang=zh_tw&edition=fundamental","pubTime":"2026-06-29 21:30","pubTimestamp":1782739825,"startTime":"0","endTime":"0","summary":"香港联交所最新数据显示，6月24日，股东施毅增持英派药业-B(07630)2万股，每股作价35.9388港元，总金额约为71.88万港元。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260629/20260629213043_51705.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260629/20260629213043_51705.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460671.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["07630","EWH","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643221934","title":"《大行》高盛列出具有納入南向交易潛力半新股(表)","url":"https://stock-news.laohu8.com/highlight/detail?id=2643221934","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643221934?lang=zh_tw&edition=fundamental","pubTime":"2026-06-15 10:44","pubTimestamp":1781491440,"startTime":"0","endTime":"0","summary":"高盛发表报告，筛选具有纳入南向交易潜力的新上市港股：MiniMax思格能源曦智科技德适生物长光辰芯群核科技深演智能商米科技云迹飞速创新剂泰科技乐动机器人云英谷科技丹诺医药泽景股份瀚天天成华曦达拓璞数控凯乐士科技驭势科技傅里叶首钢朗泽东阳光药天星医疗创想三维天辰生物极视角英派药业华研机器人 爱芯元智瑞博生物HashKey翼菲科技大金重工(港股报价延迟最少十五分钟。沽空资料截至 2026-06-12 16:25。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20251231085225954_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20251231085225954_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1529016/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1529016/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1159","03625","06872","06871","BK1109","BK1144","BK1100","02729","03887","BK1163","06656","BK1191","BK1179","06938","02726","02632","03355","02670","01779","01879","02526","BK1156","07666","BK1116","BK1169","00901","03310","BK1161","02723","BK1117","01021","BK1137","07688","07630","06636","01511","06810","00100","06887","00068","00600","01236","03388","03277","BK1193","02553","BK1149","01081","BK1147","01609"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":4,"totalSize":123,"code":"91000000","status":"200"}]}}